Drug Industry Daily: Subscribe Now!

U.S. and international regulations and guidances… warning letters and enforcement trends… drug approvals and business development… lawsuits and court decisions… intellectual property and patent issues…

If you had access to the ultimate insider — someone with an ear to the ground at FDA, FTC, HHS, EU and other key agencies and decision-making bodies affecting the pharmaceutical industry around the world — how might you use this intelligence to help your business?

Subscribe to Drug Industry Daily (DID). It is the next best thing, providing you with daily electronic updates and insights you can use to increase your competitive edge.

DID is the premier resource for pharmaceutical executives to obtain accurate insider information on the daily activities of the agencies most directly affecting their businesses:

• Use DID’s information on FDA’s pharmaceutical regulatory actions and policies to stay current with the latest industry trends and developments, ensuring you are using the most efficient and cost-effective processes.
  
• Rely on DID’s insights to impact your decisions and provide context for how to improve processes and maintain compliance, ultimately saving time and money.
  
• Use DID’s monitoring of the latest enforcement trends — including Form 483 inspection reports — to ensure your organization remains in compliance rather than losing time and money by having to create and implement corrective action plans.

DID is the secret information weapon of top pharmaceutical executives — Boehringer Ingelheim, Johnson & Johnson, GSK, Novartis, Bayer, Pfizer… —giving them a competitive edge with actionable intelligence.

Ensure you’re in-the-know today. Arm yourself with the most up-to-date news on top issues, including:

• Patent exclusivity
• Market globalization enforcement
• EU pharmacovigilance
• New inspection trends
• Advertising practices
• Warning letters
• Recalls
• Approvals
• And much more…

Get each issue of DID with links to documents that saves you time. Links include draft and final guidances, 483s and warning letters, proposed rules, closeout letters, and the full text of proposed legislation and GAO reports.

You’ll have each issue covering a specific topic, with a helpful recap at the end of each week:

Start your one-year subscription (250 issues) DID for only $1,695.

We’re confident the value DID provides you will pay for itself many times over. If you disagree, there’s our No-Risk, 100% Money-Back Guarantee: If at any time, for any reason, you become dissatisfied with Drug Industry Daily, you may cancel your subscription and receive a full refund. No questions asked.